Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer. Cooperative Study Group of Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group

Nakazato, H.; Ichihashi, H.; Kondo, T.

Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(2): 308-318

1986


ISSN/ISBN: 0385-0684
PMID: 3947108
Document Number: 269036
From July 1977, a controlled clinical trial in 168 patients who received curative surgery for stomach cancer and 111 similarly treated for colorectal cancer was conducted in the form of a cooperative study involving 22 institutions. One week after surgery, carboquon (CQ) was given at a dose of 2 mg/m2 once a week, followed by PSK at a dose of 2 g/m2 every day for 4 weeks. This regimen was repeated 9 times for 55 weeks. For stomach cancer, patients were divided into 3 groups; Group A: CQ intermittently, Group B: CQ PSK in alternate doses, Group C: controls. For colorectal cancer, the patients were divided into 2 groups; Group D: CQ + PSK in alternate doses, Group E: controls. Survival rate of stage III stomach cancer patients in Group B was higher than that in Group A, the difference being statistically significant between 20 and 24 months after surgery. For colorectal cancer, the survival rate of patients with Dukes C in Group D was statistically superior to that in Group E. These differences were much more apparent among patients who received more than 6 courses of the regimen.

Document emailed within 1 workday
Secure & encrypted payments